Serina Therapeutics Inc SER 深 沪
等待开盘 03-26 09:30:00 美东时间
3.03
+0.600
+24.69%
华盛通- 最 高3.16
- 今 开2.45
- 成交量 327.13万股
- 最 低 2.45
- 昨 收 2.43
- 总市值 3231.21万
- 52周最高 7.92
- 市盈率 静 --
- 换手率 30.68%
- 52周最低 1.22
- 委 比 23.60%
- 总股本 1066.41万
- 历史最高 209.2615
- 量 比 0.09
- 振 幅 29.22%
- 历史最低 1.22
- 每 手 1
- 风险率 1.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Serina Therapeutics Q4 EPS $(0.31) Beats $(0.46) Estimate
Serina Therapeutics (AMEX:SER) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.46) by 32.61 percent. This is a 29.17 percent decrease over losses of $(0.24) per share from
今天 04:37
Serina Therapeutics (SER) Stock Surges Over 39% After Hours— Here's Why
Serina Therapeutics Inc. surged 39.45% in after-hours trading Wednesday following a $15 million private placement announcement.
03-19 15:11
Serina Therapeutics Announces Up To $30M In Private Placement To Support Registrational Trial Of SER-252 Parkinson's Treatment
- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded warrants priced at
03-19 04:13
Serina Therapeutics enrolls first patient in Phase 1b registrational trial of SER-252 for advanced Parkinson’s disease
Serina Therapeutics enrolls first patient in Phase 1b registrational trial of SER-252 for advanced Parkinson’s disease Serina Therapeutics said it has enrolled the first patient in a global Phase 1b registrational trial of SER-252 for advanced Parkinson’s disease. The study will evaluate safety, tol
02-19 19:00
Why DarkIris Shares Are Trading Higher By Over 100%; Here Are 20 Stocks Moving Premarket
Shares of DarkIris Inc (NASDAQ:DKI) rose sharply in pre-market trading after th...
02-02 18:17
Market-Moving News for January 29th
META: 10% | Meta Platforms shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 sales guidance above estimates. TSLA: 4% | Tesla Q4
01-29 20:22
What Sparked Serina Therapeutics (SER) 35% After-Hours Surge?
Serina Therapeutics shares jumped nearly 35% after the FDA cleared its IND application for SER-252, advancing plans for a Phase 1b trial in advanced Parkinson's disease.
01-29 13:09
FDA Clears IND Application for Serina Therapeutics' SER-252 in Advanced Parkinson's Disease
FDA Clears IND Application for Serina Therapeutics' SER-252 in Advanced Parkinson's Disease Serina Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SER-252, an investigational therapy for advanced Parkinson's
01-29 05:03
Chief Scientific Officer Randall Moreadith Reports Disposal of Serina Therapeutics Inc. Common Shares
Chief Scientific Officer Randall Moreadith Reports Disposal of Serina Therapeutics Inc. Common Shares Randall Moreadith, Chief Scientific Officer of Serina Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer:
01-24 01:35
